NAV1.7 Voltage-Gated Sodium Channel

A voltage-gated sodium channel subtype found widely expressed in nociceptive primary sensory neurons. Defects in the SCN9A gene, which codes for the alpha subunit of this sodium channel, are associated with several pain sensation-related disorders.

Also Known As:

Peripheral Sodium Channel 1; SCN9A Sodium Channel alpha Subunit; Type 9 Voltage-Gated Sodium Channel; Voltage-Gated Sodium Channel Type 9; Voltage-Gated Sodium Channel Type 9 Subunit alpha; NAV1.7 Voltage Gated Sodium Channel; Type 9 Voltage Gated Sodium Channel; Voltage Gated Sodium Channel Type 9; Voltage Gated Sodium Channel Type 9 Subunit alpha

Networked: 10 relevant articles (0 outcomes, 2 trials/studies)

Bio-Agent Context: Research Results

Amino Acids, Peptides, and Proteins: 1
- Proteins: 484843

Experts

1.	Wang, Jixin: 2 articles (01/2017 - 06/2016)
2.	Amano, Taku: 1 article (09/2020)
3.	Ishikura, Kei-Ichiro: 1 article (09/2020)
4.	Ishiuchi, Kan'ichiro: 1 article (09/2020)
5.	Iwaki, Anna: 1 article (09/2020)
6.	Katasho, Maki: 1 article (09/2020)
7.	Kitajima, Masaki: 1 article (09/2020)
8.	Makino, Toshiaki: 1 article (09/2020)
9.	Nakatani, Yoshihiko: 1 article (09/2020)
10.	Negoro, Kanako: 1 article (09/2020)

Related Diseases

1.	Chronic Pain 01/01/2017 - "Studies on human genetics have suggested that inhibitors of the Nav1.7 voltage-gated sodium channel hold considerable promise as therapies for the treatment of chronic pain syndromes. "
2.	Hyperalgesia 09/15/2020 - "In the present study, we investigated whether GJG, PA, and neoline could inhibit Nav1.7 voltage-gated sodium channel (VGSC) current and whether neoline could ameliorate mechanical hyperalgesia in diabetic mice. "
3.	Neuralgia (Stump Neuralgia) 01/01/2023 - "The expression of SCN9A, which encodes the Nav1.7 voltage-gated sodium channel and ERK have been found to change significantly in many cases of neuropathic pain. " 11/27/2022 - "Reversal of Peripheral Neuropathic Pain by the Small-Molecule Natural Product Narirutin via Block of Nav1.7 Voltage-Gated Sodium Channel." 06/01/2016 - "The NaV1.7 voltage-gated sodium channel is a highly valued target for the treatment of neuropathic pain due to its expression in pain-sensing neurons and human genetic mutations in the gene encoding NaV1.7, resulting in either loss-of-function (e.g., congenital analgesia) or gain-of-function (e.g., paroxysmal extreme pain disorder) pain phenotypes. " 01/01/2020 - "We recently discovered that peripheral nerve injury-induced upregulation of an axonal guidance phosphoprotein collapsin response mediator protein 2 (CRMP2) and the N-type voltage-gated calcium (CaV2.2) as well as the NaV1.7 voltage-gated sodium channel, correlates with the development of neuropathic pain. "
4.	Erythromelalgia (Erythermalgia) 05/02/2019 - "Sporadic Erythromelalgia Associated with a Homozygous Carrier of Common Missense Polymorphism in SCN9A Gene Coding for NaV1.7 Voltage-gated Sodium Channel." 01/01/2019 - "To evaluate the clinical features of erythromelalgia in childhood associated with gain-of-function SCN9A mutations that increase activity of the Nav1.7 voltage-gated sodium channel, we conducted a systematic review of pediatric presentations of erythromelalgia related to SCN9A mutations, and compared pediatric clinical presentations of symptomatic erythromelalgia, with or without SCN9A mutations. " 02/15/2011 - "Gain-of-function mutations in the SCN9A gene (encoding to NaV1.7 voltage-gated sodium channel) cause two rare paroxysmal pain disorders: inherited erythromelalgia (IEM) and paroxysmal extreme pain disorder (PEDP). "
5.	Pain (Aches) 02/15/2011 - "Gain-of-function mutations in the SCN9A gene (encoding to NaV1.7 voltage-gated sodium channel) cause two rare paroxysmal pain disorders: inherited erythromelalgia (IEM) and paroxysmal extreme pain disorder (PEDP). " 06/01/2016 - "The NaV1.7 voltage-gated sodium channel is a highly valued target for the treatment of neuropathic pain due to its expression in pain-sensing neurons and human genetic mutations in the gene encoding NaV1.7, resulting in either loss-of-function (e.g., congenital analgesia) or gain-of-function (e.g., paroxysmal extreme pain disorder) pain phenotypes. "

Related Drugs and Biologics

1.	neoline
2.	Semaphorin-3A
3.	Proteins (Proteins, Gene)
4.	Phosphoproteins
5.	Calcium
6.	narirutin

Related Therapies and Procedures

1.	Therapeutics